Studies of Half-Lives of Long-Acting Antipsychotics are Needed

Georgios Schoretsanitis; Alejandro G. Villasante-Tezanos; Jose de Leon

doi:10.1055/a-0755-7692

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2019; 52(01): 45-46
DOI: 10.1055/a-0755-7692

Letter to the Editor

Studies of Half-Lives of Long-Acting Antipsychotics are Needed

Georgios Schoretsanitis

¹University Hospital of Psychiatry, Bern, Switzerland, and Department of Psychiatry, Psychotherapy and Psychosomatics, and JARA-Translational Brain Medicine, RWTH Aachen University, Aachen, Germany

,

Alejandro G. Villasante-Tezanos

²Department of Statistics, University of Kentucky, Lexington, KY, USA

,

Jose de Leon

³Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain, and Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain

› Author Affiliations

Abstract

Keywords

carbamazepine - CYP3A4 - delayed-action preparations - drug interaction - drug monitoring - drug-related side effects and adverse reactions - enzyme induction - injections - risperidone/administration & dosage - risperidone/blood - risperidone/metabolism - risperidone/pharmacokinetics - risperidone/pharmacology - risperidone/therapeutic use - schizophrenia/drug therapy

Full Text

References

References
1 Verdoux H, Pambrun E, Tournier M. et al. Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophr Res 2016; 178: 58-63
2 Hiemke C, Bergemann N, Clement HW. et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
3 Schoretsanitis G, Paulzen M, Unterecker S. et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; A tool for clinicians. World J Biol Psychiatry 2018; 19: 162-174
4 Baldelli S, Clementi E, Cattaneo D. Can we rely on AGNP therapeutic targets also for LAI antipsychotics?. Pharmacopsychiatry 2017;
5 Bauer LA. Clinical pharmacokinetics handbook. New York, NY: McGraw-Hill; 2006
6 Helland A, Syrstad VE, Spigset O. Prolonged elimination of paliperidone after administration of paliperidone palmitate depot injections. J Clin Psychopharmacol 2015; 35: 95-96
7 Schoretsanitis G, Spina E, Hiemke C. et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol 2017; 10: 965-981
8 Fuchs PA, Miller L, Schiff M. The use of carbamazepine to expedite metabolism of risperidone long-acting injection through induction of CYP3A4 in a patient with extrapyramidal symptoms. Am J Psychiatry 2018; 175: 579-580
9 Barnhill J, Susce MT, Diaz FJ. et al. Risperidone half-life in a patient taking paroxetine - A case report. Pharmacopsychiatry 2005; 38: 223-225